The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination
1
Inserm, U955, Equipe 16, 94000 Créteil, France
2
Faculté de médecine, Université Paris Est, 94000 Créteil, France
3
Vaccine Research Institute (VRI), 94000 Créteil, France
4
INSERM U955 Equipe 16, Université Paris-Est Créteil, Vaccine Research Institute (VRI), 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
5
AP-HP Hôpital H. Mondor—A. Chenevier, Service d’Immunologie clinique et maladies infectieuses, 94010 Créteil, France
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(3), 419; https://doi.org/10.3390/vaccines8030419
Received: 30 June 2020
/
Revised: 22 July 2020
/
Accepted: 23 July 2020
/
Published: 27 July 2020
(This article belongs to the Special Issue Therapeutic Vaccination of HIV-infected Patients)
We discuss here some of the key immunological elements that are at the crossroads and need to be combined to develop a potent therapeutic HIV-1 vaccine. Therapeutic vaccines have been commonly used to enhance and/or recall pre-existing HIV-1-specific cell-mediated immune responses aiming to suppress virus replication. The current success of immune checkpoint blockers in cancer therapy renders them very attractive to use in HIV-1 infected individuals with the objective to preserve the function of HIV-1-specific T cells from exhaustion and presumably target the persistent cellular reservoir. The major latest advances in our understanding of the mechanisms responsible for virus reactivation during therapy-suppressed individuals provide the scientific basis for future combinatorial therapeutic vaccine development.
View Full-Text
Keywords:
cytokines; immune checkpoint blockers; combinatorial intervention; HIV-1; therapeutic vaccine
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Seddiki, N.; Picard, F.; Dupaty, L.; Lévy, Y.; Godot, V. The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination. Vaccines 2020, 8, 419. https://doi.org/10.3390/vaccines8030419
AMA Style
Seddiki N, Picard F, Dupaty L, Lévy Y, Godot V. The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination. Vaccines. 2020; 8(3):419. https://doi.org/10.3390/vaccines8030419
Chicago/Turabian StyleSeddiki, Nabila, Florence Picard, Léa Dupaty, Yves Lévy, and Véronique Godot. 2020. "The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination" Vaccines 8, no. 3: 419. https://doi.org/10.3390/vaccines8030419
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
